# An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

> **NCT03060577** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 382 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease
- Symptomatic Atherosclerosis
- Type2 Diabetes
- Familial Hypercholesterolemia

## Interventions

- **DRUG:** Inclisiran
- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT03060577
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-27
- **Primary completion:** 2021-12-17
- **Final completion:** 2021-12-17
- **Target enrollment:** 382 (ACTUAL)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03060577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03060577, "An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03060577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*